Jazz Pharmaceuticals, which has a goal of bringing at least five novel medicines to the market by the end of the decade, is adding another contender to its pipeline by striking a deal for a Zymeworks drug in pivotal testing as a treatment for two cancers of the digestive system. According to the terms of the agreement announced Wednesday, Jazz […]
